4151.T
Kyowa Kirin Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 2,430.00
+1.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 510.6B | 496.8B | 495.6B | 442.2B | 398.4B |
| Cost of Revenue | 30.2B | 127.9B | 132.6B | 111.2B | 86.9B |
| Gross Profit | 88.2B | 368.9B | 362.9B | 331.0B | 311.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 41.1B | 165.4B | 167.5B | 163.1B | 166.2B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 8.1B | 18.0B | 19.3B | 21.0B | 23.1B |
| Total Operating Expenses | 49.2B | 183.4B | 186.8B | 184.1B | 189.2B |
| Cost and Expenses | 104.5B | 409.6B | 412.1B | 345.0B | 330.8B |
| Operating Income (EBIT) | 13.9B | 87.2B | 83.5B | 97.2B | 67.6B |
| Non-Operating | |||||
| Interest Income | 5.7B | 4.7B | 1.8B | 4.9B | 3.3B |
| Interest Expense | 2.3B | 3.6B | 7.5B | 190.0M | 1.1B |
| Net Interest Income | 3.4B | 1.1B | (5.8B) | 4.7B | 2.2B |
| Other Non-Op Income/Expense | 385.0M | 1.1B | 13.1B | 16.8B | 1.7B |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 13.9B | 87.2B | 83.5B | 97.2B | 67.6B |
| Income Tax Expense | 1.9B | 20.2B | 23.6B | 16.1B | 14.0B |
| Bottom Line | |||||
| Net Income | 72.9B | 67.0B | 59.9B | 81.2B | 53.6B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 72.9B | 67.0B | 59.9B | 81.2B | 53.6B |
| Per Share | |||||
| Basic EPS | ¥139 | ¥128 | ¥113 | ¥151 | ¥100 |
| Diluted EPS | ¥139 | ¥128 | ¥113 | ¥151 | ¥100 |
| Revenue Per Share | ¥975 | ¥949 | ¥936 | ¥823 | ¥741 |
| Shares | |||||
| Basic Shares Outstanding | 523.5M | 523.5M | 529.5M | 537.6M | 537.4M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 21.6B | 113.4B | 108.2B | 118.3B | 86.0B |
| D&A | 7.6B | 26.1B | 24.8B | 21.1B | 18.5B |
| EBIT | 13.9B | 87.2B | 83.5B | 97.2B | 67.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026